Summary C-myc gene activation is a common event in multiple types of neoplasia and has been associated with different cellular processes relevant to the malignant transformation of cancer cells. C-myc gene amplification has been analysed in colorectal carcinomas by means of an innovative DNA fingerprinting method based on the arbitrarily primed PCR. This method requires a low amount of DNA, uses multiple internal controls and appears sensitive and reproducible. Clinicopathological and molecular correlates have been investigated in a series of 70 colorectal carcinomas. The incidence of c-myc amplification was 26%, ranging from two-to fivefold increase in copy number. C-myc amplification occurrence was more frequent in more advanced stages of tumour invasion (P < 0.001) and was associated with mutations in the p53 tumour-suppressor gene (P = 0.048). The presence of c-myc amplification was indicative of a shorter disease-free survival period but, because of its strong association with Dukes' stage, its prognostic value is questionable.
After the initial finding of an amplified c-myc gene (also known as MYC) in different human cell lines (Collins and Groudine, 1982; Alitalo et al, 1983; Little et al, 1983) , oncogenic activation of the c-myc gene through amplification has been demonstrated in multiple types of cancer (reviewed by Bishop, 1991; Garte, 1993) . Previous studies have shown that c-myc gene amplification and/or overexpression in colorectal cancer correlates with the degree of invasion (Kozma et al, 1994; Sato et al, 1994) and poor differentiation (Heerdt et al, 1991) . Nevertheless, other authors have failed to find such associations (Erisman et al, 1988; Finley et al, 1989; Matsumara et al, 1990; Nagai et al, 1992; Smith et al, 1993) . Although c-myc overexpression appears in an elevated proportion of tumours (66-90%) Matsumara et al, 1990; Smith et al, 1993; Sato et al, 1994; Wang et al, 1994) , gene amplification, as determined by Southern Untawale and Blick, 1988; Finley et al, 1989; Matsumara et al, 1990; Heerdt et al, 1991) or dot-blot hybridization (Erisman et al, 1988; Nagai et al, 1992; Smith et al, 1993; Kozma et al, 1994; Wang et al, 1994 ) is less frequent, ranging from 0 to 30%. In addition to the intrinsic complexity of cellular processes, sample heterogeneity and methodological pitfalls are important factors that puzzle the comprehensibility of these divergences.
With the advent of the polymerase chain reaction (PCR) and in order to overcome the limitation of blot hybridization techniques (mainly, a high amount of genomic DNA is required), different quantitative PCR methods for c-myc analysis have been developed (Rhoer-Moja et al, 1993; Watson et al, 1993; Sugimoto et al, 1994; Sestini et al, 1995) . PCR co-amplification of the c-myc gene with an internal control did not render reliable results in our hands. Theoretical and practical considerations limit the accuracy of this type of technique, often generating irreproducible results (see review by Ferre et al, 1994) .
The initial aim of this study was to determine the possible relationship between c-myc gene amplification and molecular and clinicopathological variables in a series of colorectal carcinomas. As only a limited amount of DNA was available from normal and tumour tissue (making the use of hybridization-type methods impossible) and in order to overcome the technical limitations described above, we have set up a PCR-derived method that uses multiple internal and arbitrary controls. This technique is based on the arbitrarily primed PCR (AP-PCR) (Welsh and McClelland, 1990) , a fingerprinting-type technique using primers whose nucleotide sequence is arbitrarily chosen.
It has been demonstrated that AP-PCR is useful for the detection and isolation of tumour-specific allelic losses and gains (Peinado et al, 1992; Kohno et al, 1994; Achille et al, 1996) , thus providing a molecular alternative to cancer cytogenetics. In addition, DNA fingerprinting by AP-PCR permitted the discovery of ubiquitous somatic genomic instability in a subset of colorectal tumours (Ionov et al, 1993) . More recently, AP-PCR fingerprinting has been used to estimate the degree of genomic damage in colorectal tumours (Bocker et al, 1996; Arribas et al, 1997; Basik et al, 1997) . We have observed that the rate of genomic damage in neoplastic cells, as determined by AP-PCR, may have important prognostic applications (Arribas et al, 1997) . Two intrinsic features of AP-PCR are of special interest: (a) the amplified sequences proceed from randomly selected genome regions with no apparent bias for the chromosomal origin of the bands (Peinado et al, 1992; Yasuda et al, 1996) ; and (b) the amplification is quantitative in that the intensity of an amplified band is proportional to the concentration of its corresponding template sequence (Peinado et al, 1992; Perucho et al, 1995) .
In our approach, primers are designed to amplify a fragment including the third exon of the human c-myc gene and PCR is performed under low-stringency conditions, as in AP-PCR. In consequence, the c-myc gene fragment is co-amplified with a number of arbitrary sequences that consistently appear in all the samples. These sequences are flanked by the same primers as the c-myc gene and competition among them generates a quantitative fingerprint (see scheme in Figure 1 ). Furthermore, we can expect D   6  44  51  57  58  60  66  83  89  119  135  180   33  36  42  45  47  48  49  55  59  62  68  78  91  100  118  121  132  136  150  153  188  190  193   27  56  94  96  101  117   134   137  156  189  191  192  201  202  213   65  80  125  133  182  197  268   77  77  67  71  69  75  76  73  39  61  79  55   61  80  77  76  59  81  60  68  56  62  73  62  53  60  70  66  71  58  69  63  56  63  68   63  76  56  66  61  93  62  71  60 We have applied TAP-PCR to the allelic dosage of the c-mvc gene in a series of colorectal tumours of which a limited amount of DNA was available. We have observed moderate c-myc gene amplifications in about one-quarter of the tumours. Amplifications of the c-mvc gene occurred more frequently in advanced stages of tumour invasion and were associated with mutations in the p53 gene.
MATERIAL AND METHODS Samples
Seventy colorectal carcinomas and paired normal tissue samples were obtained from the Human Tissue Cooperative Network (University of Alabama, Birmingham, USA). Phenotypic and genetic characteristics of these cases have been described elsewhere as part of a larger series (Capella et al, 1991; Peinado et al, 1993) . The samples used in this study were selected from a collection of 181 cases based on availability of genomic DNA from tumour and paired normal mucosa. They were representative of the whole collection for all the molecular and clinicopathological parameters considered. Cases were pathologically staged using Astler-Coller modification of Dukes' classification system. Detailed histological study of a short series of cases revealed that in most cases (16 out of 17) more than 75% of the analysed tissue was composed of neoplastic cells. In a single case, stromal and normal epithelial cells constituted approximately 50% of the tissue. SW480 and DLD-1 cell lines (ATCC, Rockville, MD, USA) were used as positive and negative controls, respectively, for c-mvc amplification. Cases with perioperative deaths and with insufficient follow-up were excluded from the survival analysis.
Molecular analyses Genomic DNA was extracted by the phenol-chloroform method as described previously (Nakano et al, 1984) . DNA was diluted to a concentration of 20 ng gl-l and 1 gl of each DNA was run in a A Targeted arbNradly pnrmed PCR (TAP-PCR) 0.75% agarose gel and stained with ethidium bromide to verify its quality and concentration. When necessary, the DNA concentration was adjusted according to the ethidium bromide signal. Mutations at codons 12 and 13 of the K-ras gene and 12 of the Nras gene were detected and characterized by the artifical RFLP/PCR approach (Capella et al, 1991) . p53 mutations in exons 4-9 were analysed using single-strand conformation polymorphism (SSCP) of PCR amplified products and characterized by direct cycle sequencing of the PCR product . Genomic instability at simple repeated sequences was analysed in microsatellite sequences AP2, AP3, Mfd27, Mfd41 and Mfd47 as described previously (Ionov et al, 1993; Shibata et al, 1994) . Cases showing instability in two or more microsatellites were considered to belong to the microsatellite mutator phenotype (MMP) pathway. In agreement with other reports (Thibodeau et al, 1993) , tumours with low genomic instability (mutations in only one out of five microsatellite sequences analysed) present molecular and biological characteristics different from those with high instability but similar to the rest. In consequence, they were considered MMP negative.
TAP-PCR of c-myc
TAP-PCR reactions were performed in duplicate with 50ng of genomic DNA, 125 gM each dNTP, 1 gM each primer (sense:
Buckinghamshire, UK) and 1.25 units of Taq polymerase (Boehringer Mannheim, Mannheim, Germany) in PCR buffer (10 mm Tris-HCl pH 8.0, 50 mm potassium chloride, 1.5 mm magnesium chloride) in a final volume of 25 gl. The reaction consisted of five low-stringency cycles (30 s at 94°C, 30 s at 50°C, 30 s at 72°C) and 35 high-stringency cycles (30 s at 94°C, 30 s at 65°C, 30 s at 72°C) and was carried out in a PTC-100 thermocycler (MJ Research, Watertown, MA, USA). The product was diluted with formamide dye buffer, denatured for 3 min at 95°C and 3 ,ul were run on a 6% acrylamide 8 M urea sequencing gel at 55 W for 3 h. The gels were dried under vacuum at 85°C and exposed to radiograph film at room temperature without intensifier screen for 1-3 days. The amplified c-myc region corresponds to a fragment 470-bp-long, which includes Conventional PCR amplification using specific primers (A) will produce a unique product corresponding to the sequence flanked by the primers and resolved as a unique band by gel electrophoresis (lane A). When low stringency conditions are applied, primers are likely to anneal to multiple regions of the genome (B and C) and many sequences are co-amplified in a competitive and reproducible fashion, including the one for which the primers are designed (lanes B and C) . In this case, differences in copy number of the targeted sequence will be manifested as proportional changes in the amount of its corresponding TAP-PCR product band as resolved by electrophoresis. Right panel corresponds to a 6% polyacrylamide (non-denaturing) gel electrophoresis of c-myc amplification in the conditions described above. Lanes B and C contain the TAP-PCR products from a normal and its paired tumour DNA respectiveiy. Gel was stained with ethidium bromide and colour inverted the third exon. The identity of the c-mvc band was checked by simultaneous electrophoresis of the TAP-PCR product with the product of a conventional high-stringency PCR (annealing temperature, 65°C). The co-migrating band was isolated, cloned and sequenced using standard procedures (Peinado et al, 1992; Perucho et al, 1995) . Differences in the intensity of bands between the tumour and its paired normal tissue were ascertained by direct eye inspection of the film. Relative increases in intensity of the c-myc band in the tumour sample compared with its normal sample was considered a symptom of gene amplification compared with the co-amplified arbitrary bands. In addition, in order to have an objective measurement of the magnitude of the change, films were scanned and the intensity of bands quantified using Phoretix I D software (Newcastle upon Tyne, UK). The intensity of each c-myc band was divided by the sum of five arbitrary bands (Figure 2 ) in order to have a relative measure when the overall intensity of the lanes was not comparable. The ratio between normal tissue and tumour tissue was used to determine the degree of amplification of the c-myc gene in each case.
Method assessment
To test the sensitivity of this technique, duplicated serial dilutions of the SW480 DNA in the DLD-1 DNA were analysed using TAP-PCR and Southern blot hybridization. TAP-PCR was performed as described earlier. For Southern blot analysis, 10 ,ug of DNA was digested with Xba 1 restriction endonuclease (New England Biolabs, Beverly, MA, USA) and electrophoresed on a 0.7% agarose gel. DNA denaturation and transfer to a blotting membrane (Quiabrane, Quiagen, Santa Clarita, CA, USA) was performed using standard procedures (Sambrook et al, 1989) . The filter was hybridized overnight with a c-myc probe labelled using the random primer method (Prime-It, Stratagene, La Jolla, CA, USA) with [t-32P]dCTP (Amersham). The probe was obtained by cloning a PCR product generated with the same primers used for TAP-PCR. The probe was sequenced to confirm its identity.
Statistical analysis
Statistical analysis was performed using the chi-square test, ANOVA or unpaired t-test as appropriate. Contingency tables were analysed using Fisher's exact test or the chi-square test. Fifty-seven cases were included in the follow-up study (Table 1) . Given the limited size of our series with complete follow-up and taking into account that five cases presented a late recurrence of the disease (6 or 7 years after surgery), to determine the potential application of c-myc amplification as a prognostic factor it was considered more appropriate to use the disease-free survival interval rather than the overall survival. Disease-free survival distributions were calculated using the Kaplan-Meier method and British Journal of Cancer (1998) analysed using the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model. Statistical analysis was performed with SPSS software. All P-values are estimated from two-sided statistical tests.
RESULTS

Method assessment
Sequencing of the TAP-PCR band co-migrating with the specific PCR c-myc product (Figure 1 ) demonstrated its identity. Technique sensitivity was determined by serial dilutions of the SW480 DNA in the DLD-1 DNA and compared with southern blot hybridization. Parallel results were obtained with both techniques (Figure  2) . The maximum dilution of SW480 in DLD-1 that appeared to be distinguishable from uncontaminated DLD-1 was 1:31. As determined by densitometric analysis of the Southern blot hybridization, the c-myc gene is about 13.5 ± 0.8 (mean ± s.d.)-fold amplified in SW480 vs DLD-1, whereas using TAP-PCR it was 10.8 ± 0.7. This implies that a 1:31 dilution of SW480 DNA in DLD-1 DNA will correspond to a 1.4 c-myc amplification for DLD-1. As shown in Figure 2 , TAP-PCR analysis is able to resolve such tiny differences, indicating that the sensitivity of the method is below a 1.5-fold amplification.
in Figure 3 . The amplification ratio ranged from two-to fivefold with an average of 3.05 ± 1.02 (mean ± s.d.). Owing to the heterogeneous proportion of tumour cells in a given sample, tumours have been classified as positive or negative for c-myc amplification, taking into account that we have a minimal estimation of the amplification ratio. Clinicopathological and molecular associations of the c-myc amplification are summarized in Table 2 . Lymph node-positive cases showed a higher incidence of c-myc amplification (47%) vs no lymph invasion (10%) (P = 0.0005). No differences were observed between Dukes' stages C and D. In tumours containing a mutation in the p53 gene, c-myc was more often amplified (P = 0.0484). No significant correlation was found with other variables such as age, sex, race, tumour differentiation and location and presence of mutations in the ras gene. None of the eight tumours displaying microsatellite instability contained an amplified c-myc; nevertheless, the differences did not reach statistical significance.
Univariate survival analysis for the different parameters studied (Table 3) indicated that advanced Dukes' stages and poor differentiation were markers of bad prognosis. Although cases with amplification of the c-myc gene also had a poorer disease-free survival (log-rank, P = 0.0628), due to its strong association with more advanced stages, it does not constitute an independent prognostic factor as determined by multivariate Cox analysis (Table 3) .
c-myc amplification in colorectal carcinomas
Taking into account the sensitivity of the technique and that our tumour samples were likely to contain a significant proportion of non-tumour cells, a minimal 1.5-fold increase in intensity in the tumour compared with the normal was required to be considered as an amplification. An intensity of the c-myc band in the tumour tissue vs its paired normal tissue (> 1.5-fold) was observed in 18 out of 70 cases analysed (26%). An Owing to the intrinsic instability of the cancer cell genome, use of multiple and diverse reference loci is an indispensable condition. In consequence, one of the properties of AP-PCR, the random chromosomal origin of the co-amplified bands (Peinado et al, 1992; Yasuda et al, 1996) , is of special relevance to guarantee the accuracy of the quantification.
The incidence of c-myc amplification in our series of colorectal tumours is in the upper range (about 25%) of the data reported in the literature, in agreement with Heerdt et al (1991) and Wang et al (1994) . As the amplifications we have seen are moderate (threefold in average), a lack of sufficient sensitivity may explain the failure of other studies to detect such gains. Although not significant, we have observed a lower incidence of c-myc amplification in the right-side colon (Table 2 ). This is in agreement with a previous study in which c-myc overexpression was more frequent in the left colon . In fact, these authors have already defined two pathways for sporadic colorectal tumours in relationship to the familial syndromes. Tumours behaving like hereditary non-polyposis colorectal cancer (HNPCC) were located at the right side and did not overexpress c-myc, whereas tumours behaving like familial polyposis coli were left sided and showed c-mvc activation. In agreement with this observation, more recent evidence has shown that a significant proportion of the right-sidelocated tumours progress through a different molecular pathway characterized by a DNA mismatch repair-deficient machinery Ionov et al, 1993; Lothe et al, 1993; Peltomaki et al, 1993; Thibodeau et al, 1993; Perucho et al, 1994) . These tumours do not show c-mvc amplification (Table 2) and, in consequence, might be responsible for this trend.
Although there is a general agreement that c-myc amplification is more frequent in more aggressive tumours, including colorectal, gastric and lung (Heerdt et al, 1991; Yokota et al, 1986; Little et al, 1983; Shibuya et al, 1985) , because of sample and technical heterogeneity data are barely comparable. Tumours depicting cmvc amplification show a poorer disease-free and overall survival. Unfortunately, the relevance of this association has a doubtful application. The clear correlation with advanced Dukes' stages indicates the dependency between both variables. This observation also holds for overall survival. In consequence, assessment of cmyc dosage status does not seem to be useful as a prognostic factor. c-myc amplification is one of the multiple alterations that accumulates during the tumour progression and its late appearance suggests that it does not play a significant role in the transformation of the cell. Nevertheless, experimental evidence shows that c-myc activation (which is not necessarily produced by gene amplification) has a direct and important implication in multistage carcinogenesis (Field and Spandidos, 1990) . The apparent irrelevance, at clinical level, of c-mvc activation in colorectal cancer is in a way expected and explained, at least in part, by its late occurrence. It can be hypothesized that either the activation mechanism (amplification) is a late event, or the selective advantage that it confers to the tumour cell is only displayed in late stages. This is based on studies that indicate that c-myc activation induces apoptosis (Evan et al, 1992) . In consequence, for tumour cells, c-myc amplification in colorectal cancer 2355 apoptosis overriding by activation/inactivation of other factors (see Stewart, 1994 for review) would be a prerequisite before cinvc amplification can occur. In fact, this hypothesis is supported by our observation that c-myc amplification is associated with mutations in the p53 gene (one of the inductors of apoptosis). In this case, p53 inactivation [that presumably occurs in the adenoma-carcinoma transition (Fearon and Vogelstein, 1990)] will play a double role to facilitate c-myc activation, on one side by inducing apoptosis abrogation (Yonish-Rouach et al, 1991; Shaw et al, 1992 ) and on the other by overriding of the genomic stability controls (Lane, 1992) that might prevent gene amplification (Livingstone et al, 1992; Yin et al, 1992) . The positive correlation between c-myc activation and mutations in the p53 gene (Table 2) supports this hypothesis.
Although we have stated gene 'amplification' as all copy number increases observed at the c-myc level, this should be regarded with caution, especially in view of the modest nature of such increases. In addition, random screening of the cancer cell genome by AP-PCR has revealed that many anonymous bands located in chromosome 8 (as it is the c-mvc gene) also display frequent gains, which in some cases are associated with c-myc amplification (two out of five) (unpublished data). This implies that the 'amplified' fragment may include a wide chromosomal region. If this is the case, such gains might affect a large region, if not all, of chromosome 8. This argument has relevant implications for two reasons: first, the number of genes displaying gains would be very high, and, in addition to c-mvc, many of these genes may affect tumour behaviour. Second, the mechanism causing such imbalances is probably different from the one producing small regional amplifications. Precise characterization of the involved chromosomal fragment should answer such questions. Interestingly, extensive AP-PCR genome analysis of human cell lines carrying amplified c-mvc genes showed that all of them displayed concurrent amplification of other DNA fragments mapped to chromosome 8 (Okazaki et al, 1996) . Okazaki et al (1996) hypothesize that these sequences are part of an amplification unit that includes the c-mvc gene. The total size of the amplified region in a small-cell lung carcinoma cell line was estimated to be 7.5 Mb. A possible inaccuracy in our results is the quantification of the c-nvc copy number in tumour samples. Heterogeneous population and contamination by normal cells might mask the real degree of amplification. For this reason, we have only classified tumours as positive or negative for c-mVc amplification, taking into account that we have a minimal estimation of the amplification ratio. Although the technique we have used is sensitive enough to detect a relatively small amplification in a relatively small proportion of the cells, it is obvious that this limitation will affect in a lower grade more advanced tumours and consequently may mislead in the interpretation of the results. In summary, TAP-PCR appears to be an appropriate technique to determine gene amplification. The low requirement of DNA template and the simplicity of the technique indicates that it may be especially useful in the analysis of small pieces that provide insufficient amounts of material for analysis using other techniques. Our study clearly demonstrates a significant incidence of c-myc amplification in colorectal cancer and its association with invasiveness. Owing to the complexity of c-mvc function in cellular processes, further studies are required to elucidate the participation of c-myc amplification in aetiogenesis and the consequences that it may have for tumour progression.
